Tercica

Overview

• Industryhealth care¹
• HeadquartersBrisbane, California¹
• Incorporated inDE⁴
• Business address2000 Sierra Point Parkway, Suite 400, Brisbane, Ca 94005⁴

See how the biggest companies compare on our leaderboards

Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.³

Leadership

Who has led Tercica, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJohn A. Scarlett Mar 14, 2006 to Oct 20, 2008⁵
• Chief financial officerSusan Wong Mar 14, 2006 to Mar 14, 2006⁶
• Chief financial officerAjay Bansal Mar 29, 2006 to Oct 20, 2008⁷

Timeline

1. Mar 14, 2006New chief executive John A. Scarlett becomes CEO⁵

SEC filer profile

How Tercica is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARTERCICA INC²
• CIK0001262175
• Employer ID (EIN)26-0042539²
• Incorporated inDelaware²
• Fiscal year endsDecember 31²
• Industry code (SIC)2834 Pharmaceutical Preparations²
• Business address2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005²
• Phone6506244900²
• On EDGAR sinceSep 12, 2003²
• Filings378 in all: 4 (110), 8-K (75), 3 (34), 3/A (17), 10-Q (14), CT ORDER (10), S-1/A (10), SC 13D/A (10)²
  All 42 form types

  SC 13G/A (9), DEFA14A (8), S-8 POS (6), SC 13G (6), UPLOAD (6), DEF 14A (5), S-8 (5), 10-K (4), ARS (4), CORRESP (4), SC 13E3/A (4), 4/A (3), SC 13D (3), 424B4 (2), 424B5 (2), 8-A12G (2), EFFECT (2), POS AM (2), PRE 14A (2), PRER14A (2), REGDEX (2), S-1 (2), S-3 (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 5 (1), DEFM14A (1), DFAN14A (1), FWP (1), PREM14A (1), REGDEX/A (1), RW (1), SC 13E3 (1)

• Latest filingsAnnual report (10-K) Feb 29, 2008
  Quarterly report (10-Q) Aug 6, 2008
  Proxy statement (DEF 14A) Apr 25, 2008
  Latest 8-K (8-K) Oct 22, 2008

Links

• WikipediaTercica
• WikidataQ7701683
• SEC EDGARCIK 1262175